|
注册号: Registration number: |
ChiCTR2500109262 |
|
最近更新日期: Date of Last Refreshed on: |
2025-09-16 10:07:56 |
|
注册时间: Date of Registration: |
2025-09-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
微创腔镜术后患者肺功能康复方案的优化与创新研究 |
|
Public title: |
Optimization and Innovation of Pulmonary Rehabilitation Protocols for Patients Undergoing Minimally Invasive Laparoscopic Surgery |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
微创腔镜术后患者肺功能康复方案的优化与创新研究 |
|
Scientific title: |
Optimization and Innovation of Pulmonary Rehabilitation Protocols for Patients Undergoing Minimally Invasive Laparoscopic Surgery |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
韦海涛 |
研究负责人: |
韦海涛; 李丽 |
|
Applicant: |
Haitao Wei |
Study leader: |
Haitao Wei; Li Li |
|
申请注册联系人电话: Applicant telephone: |
+86 137 0378 6236 |
研究负责人电话:
Study leader's |
+86 137 0378 6236 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
10210051@vip.henu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
10210051@vip.henu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河南省开封市龙亭区金明大道北段 |
研究负责人通讯地址: |
河南省开封市龙亭区金明大道北段 |
|
Applicant address: |
Henan Province,Kaifeng City, Longting District, North Section of Jinming Avenue |
Study leader's address: |
Henan Province,Kaifeng City, Longting District, North Section of Jinming Avenue |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
河南大学 |
||
|
Applicant's institution: |
Henan University |
||
|
研究负责人所在单位: |
河南大学 |
||
|
Affiliation of the Leader: |
Henan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
HUSOM2025-799 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
河南大学生物医学科研伦理分委员会 |
||
|
Name of the ethic committee: |
Biomedical Research Ethics Subcommittee of Henan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-08-22 00:00:00 | ||
|
伦理委员会联系人: |
姬新颖 |
||
|
Contact Name of the ethic committee: |
Xinying Ji |
||
|
伦理委员会联系地址: |
河南省开封市龙亭区金明大道北段 |
||
|
Contact Address of the ethic committee: |
Henan Province,Kaifeng City, Longting District, North Section of Jinming Avenue |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 135 9212 6669 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
河南大学 |
||||||||||||||||||||||
|
Primary sponsor: |
Henan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河南省开封市龙亭区金明大道北段河南大学金明校区 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Jinming Campus of Henan University, North Section of Jinming Avenue, Longting District, Kaifeng City,Henan Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
受河南省科技厅科技攻关项目资助 |
||||||||||||||||||||||
|
Source(s) of funding: |
Supported by the Science and Technology Project of Henan Provincial Science and Technology Department |
||||||||||||||||||||||
|
研究疾病: |
肺癌 |
||||||||||||||||||||||
|
Target disease: |
Lung Cancer |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
系统评价不同肺康复干预策略对微创腔镜术后患者肺功能恢复的临床疗效,旨在构建基于循证医学的优化康复方案。 |
||||||||||||||||||||||
|
Objectives of Study: |
A systematic review of the clinical efficacy of different pulmonary rehabilitation intervention strategies on the recovery of pulmonary function in patients undergoing minimally invasive laparoscopic surgery, aiming to develop an evidence-based optimized rehabilitation protocol. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1)合并其他恶性肿瘤。 (2)合并严重心、肺、肝、肾等重要脏器功能障碍。 (3)非首次肺癌手术(如既往二次VATS手术或开胸手术史)。 (4)因肢体缺损或极度虚弱等原因无法完成研究项目者。 (5)预期生存时间<6个月者。 (6)依从性差且中途退出研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1)Combined with other malignant tumours. (2)Combined severe cardiac, pulmonary, hepatic, renal and other vital organ dysfunction. (3)Non-first surgery for lung cancer (such as previous secondary VATS procedures or open thoracic surgery history). (4)Those who are unable to complete the research project due to defective limbs or extreme physical weakness, etc. (5)Those with an expected survival time of <6 months. (6)Those with poor compliance and who withdrew from the study midway. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-09-16 00:00:00至 To 2026-09-16 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-09-16 00:00:00 至 To 2026-06-15 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机序列由独立统计人员采用随机数字表法生成,通过区组随机化控制组间平衡,分配结果采用密封信封法实施隐藏。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The random sequence was generated by an independent statistician using a random number table method, with block randomization applied to maintain inter-group balance, and the allocation results were concealed using sealed envelope method. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
预计2026年9月在ResMan平台共享http://www.medresman.org.cn/login.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
It is expected to be shared on the ResMan platform in September2025(http://www.medresman.org.cn/login.aspx) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
无 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
None |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |